<DOC>
	<DOCNO>NCT01020357</DOCNO>
	<brief_summary>Apnea prematurity common condition usually treat methylxanthines . Methylxanthines adenosine receptor blocker powerful influence central nervous system . However , little know long-term effect methylxanthines develop brain . The Caffeine Apnea Prematurity-Sleep ( CAP-S ) Study sub-study main Caffeine Apnea Prematurity ( CAP ) trial , international placebo-controlled randomize trial methylxanthine therapy apnea prematurity . This sub-study design take advantage cohort ex-premature , 5-7 year old child randomize birth receive either caffeine placebo , currently receive detail neurocognitive behavioral assessment CAP trial .</brief_summary>
	<brief_title>Caffeine Apnea Prematurity-Sleep ( CAP-S ) Study</brief_title>
	<detailed_description>The use methylxanthines therapy apnea prematurity may double-edged sword . Although widely-used , efficacious treatment apnea prematurity , long-term drug effect rigorously study . Neonatal methylxanthine therapy may long-term impact sleep organization ventilatory control . The CAP trial , fund Canadian Institutes Health Research , initiate due paucity well-controlled data long-term effect methylxanthines preterm infant . The initial CAP trial multicenter , randomize , placebo-controlled trial caffeine v placebo treatment apnea prematurity follow-up correct age 18 month . 2,006 infant enrol . The CAP trial find methylxanthines reduce rate bronchopulmonary dysplasia ( BPD ) cerebral palsy ( CP ) , affect mortality . However , concern remain regard long-term sequela methylxanthine use . The Canadian Institutes Health Research therefore fund follow-up entire CAP trial cohort age 5 year , correct prematurity . The key objective study examine impact methylxanthines neurocognition behavior . This ongoing parent study provide opportunity determine potential long-term effect methylxanthines sleep disorder , correlate finding daytime function . Our overall hypothesis methylxanthine use preterm infant , beneficial short term , result longstanding abnormality regulation sleep , breathe sleep .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Caffeine citrate</mesh_term>
	<criteria>Males female age 57 year enrol CAP trial . Parental/guardian permission ( informed consent ) appropriate , child assent .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>preterm infant</keyword>
	<keyword>low birthweight</keyword>
	<keyword>apnea prematurity</keyword>
	<keyword>methylxanthines</keyword>
	<keyword>sleep disturbance</keyword>
	<keyword>obstructive sleep apnea syndrome</keyword>
	<keyword>polysomnography</keyword>
	<keyword>sleep disruption</keyword>
</DOC>